Approved June 1998
Schering-Plough Corporation announced that the Food and Drug Administration (FDA) has approved the combination use of REBETOL (TM) (ribavirin, USP) Capsules and INTRON A (R) (interferon alfa-2b, recombinant) Injection, to be marketed as REBETRON (TM) combination therapy, for the treatment of chronic hepatitis C in patients with compensated liver disease who have relapsed following alpha interferon therapy. Prior to REBETRON (RM) combination therapy, the only drugs approved in the US for treating hepatitis C had been alpha interferons.
The REBETRON (TM) Combination Therapy drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.